Trial · NCT03979313
Results by group46
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 46
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Placebo | Observed events through day 150 post dose | 8 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Observed events through day 150 post dose | 6 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Placebo | Subjects requiring imputation (subjects without events and not followed through 150 days post dose) | 6 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Subjects requiring imputation (subjects without events and not followed through 150 days post dose) | 15 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Placebo | Subjects without event through day 150 post dose | 482 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Subjects without event through day 150 post dose | 973 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Placebo | Observed events through day 150 post dose | 25 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Observed events through day 150 post dose | 12 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Placebo | Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 6 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 15 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Placebo | Subjects without event through day 150 post dose | 465 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (Primary Cohort) | Medi8897 | Subjects without event through day 150 post dose | 967 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Placebo | Observed events through day 150 post dose | 54 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Medi8897 | Observed events through day 150 post dose | 24 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Placebo | Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 17 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Medi8897 | Subjects requiring imputation (Subjects without events and not followed through 150 days post dose) | 31 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Placebo | Subjects without event through day 150 post dose | 932 | Participants | |
| Number of Participants With MA RSV LRTI Through 150 Days Post Dose (All Subjects) | Medi8897 | Subjects without event through day 150 post dose | 1954 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects) | Placebo | Observed events through day 150 post dose | 20 | Participants | |
| Number of Participants With MA RSV LRTI With Hospitalisation Through 150 Days Post Dose (All Subjects) | Medi8897 | Observed events through day 150 post dose | 9 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03979313/results